Cylance CylancePROTECT price per endpoint matrix CylancePROTECT is an endpoint security solution by Cylance that starts at $45 per end-point for 1-99 end points. Price decreases based on volume to $36 for up to 5,000 end points and $26 for over $50,000.
Full Answer
How much does Cylance protect cost?
CylancePROTECT is an endpoint security solution by Cylance that starts at $45 per end-point for 1-99 end points. Price decreases based on volume to $36 for up to 5,000 end points and $26 for over $50,000. It detects, prevents, and block threats. …
What does the company Cylance do?
Cylance, Inc. provides cyber-security products and services. The Company develops security software solutions for critical infrastructure applications. Cylance serves and markets security solutions to companies, governments, and end-users worldwide.
What is Cylance endpoint security?
From Cylance.com “Cylance has redefined endpoint security. Our products and services predict and prevent, rather than reactively detect, the execution of advanced threats. Deployed on over 14.5 million endpoints, we protect clients worldwide including Fortune 100 organizations and governments.”
What is Cylance AI?
Cylance applies artificial intelligence, algorithmic science and machine learning to cybersecurity to prevent advanced security threats. Built on a predictive analysis process, the Cylance AI Platform serves as a foundation for the company's AI-driven security products to address critical attack vectors. The company’s flagship product, CylancePROTECT, aims to quickly and accurately identify what is benign and what is a threat, and prevent malicious code from executing on a targeted system. By coupling machine learning and artificial intelligence with an understanding of an attacker’s mentality, Cylance aims to provide technology and services that are predictive and preventive against advanced threats.
Does Equity Zen have a Cylance endorsement?
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Cylance or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature. Some data provided by Crunchbase.
Cylance Comparisons
ate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proiden
Cylance Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Who is Clene Nanomedicine?
(NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced that Rob Etherington, President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 a.m. ET. A we
How much cash was used in the first quarter of 2021?
The decrease in cash during the first quarter ended March 31, 2021 was primarily due to approximately $9.2 million of net cash used in operating activities, $0.2 million of net cash used in investing activities, and $1.9 million of net cash used in financing activities.
Is CNM-Au8 a bioenergetic drug?
Age is the best-known risk factor for the disease. There is currently no known treatment that can stop or halt the progression of this disease. About CNM-Au8 Clene’s lead drug candidate, CNM-Au8, a bioenergetic nanocatalyst, is a stable, aqueous suspension of catalytically active gold (Au) nanocrystals.
